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Cys421 and Cys-429 of Glut I wcrc npluccd hy Silc-dircctcd mutupcncsis in order IO invcstigatc their involvcmcnt in brlul &cosc tmnPp?R and 
trttarpan inhibition, Ncithcr of the two cyslcinc rcsiducs ww cucntiul for brsnl Sdroxy-~glucosc uptake in X;nq~x oecylcs expressing the 
rcspsctivc mutunt M421 und M429. If applied from thr cxlcrnul side. the pwrly pcrmcublc sullhydryl-reactive ilgrnt pCMBS inhibited 2-dcaxy-1~- 
glucorc uptrrkc of GlutI- and M4Scxprwsiny Xe~uprti oecylcx but fnilcd to aflccccr uptake ofthbCyr429 muiunt. This is in ugrccmrnt with the 
proposed two-dimcnrionitl model of Cilull confrminy tbl Cys429 ir the only rcsiduc cxposcd to the surface of the plasma mcmbrrnc. The 
rcpbccmcnt af Cyr-431 PI the cxofnrirl end OT helix clcrcn e;luscd it pilrtial proic&n of 3.bmcthylglucozc transport inhibition by CB: this raiduc 
ma)’ that bc inralti in rtabilirxinE an 1;dj:j,ccnt local ter~hry strueiurc nccessury for the full uctivily of this inhibitor. 
Glut I #ucor lranrpartcr: Xrtftiptt~ ooqtc: Cyrtcinc mutunt 
1. INTRODUCTION 
Molecular cloning has led to the identification of 5 
different glucose transporters of the f;rcilitntivc type. 
numcd Glurl through GlutS (rcvicwcd in [l-S]), Dc- 
rived from the nuclcotidc squcnces of the cDNA the 
Glut 1 glucose transporter is known to contain 6 cystc- 
ine residues [6]. Apart from Cys-347, all cystcincs arc 
located towards the ends of nn a-helix and nrc cxpcctcd 
to be in an aqueous environment, According to the 
two-dimcnsionul model of Glut1 based on hydropathy 
plots, Cys-421 is locutcd within an ‘amphipnthic’ scg 
mcnt of helix 11 whcrcos Cys-429 is cxposcd to the cell 
surfticc. During conformationnl changes of the &osc 
trasnportcr the cystcincs at position 421 and 347 might 
also bc exposed then being asccssiblc to rctlgcnts from 
the cxofxinl side of the plasma membrane (reviewed in 
P*711* 
port inhibition by CB. X~~nopu.s oocytcs wcrc uxd as a 
suitable cell system [l&12] which after injection of the 
rcspcctivc mRNAs functionally ~xprcsscd the trttns- 
porter proteins of the wild-typ Glut1 and the cystcinc 
mutants. 
2. EXPERlMENTAL 
2.1, Eit~kccrirt,q of G/u! I rrtutatiottr curd irk vitro +vttAcsti u/atRNA 
A 2.4 kbp 811l1tHl fragment dcrivcd from pSPGT [Is] wus rub- 
cloned into pBlucscript SK’ (Srrutogcnc. Hcidclbcrg. Gcrmnny). Site- 
dircclcd mutrpcnair was prformcd uscording to the praccdurc of 
Kunkcl CI el. [I$] using a BioRad kit (Bio-Red. Mllnchcn, Germany). 
The resulting changes of the mutagenic oligonuclcotida und the 
umino acids arc us follows: 
Structure-function studies of Glut1 by the USC of sitc- 
dircctcd mutagenesis have been restricted so far to the 
role of the tryptophan r&dues concerning their role in 
Bluccsc transport and inhibition nftcr CB treatment 
[89]. Wcrc WC investigated the function of the residues 
Cys-421 and Cys-429 of Glut1 for (1) the basal glucose 
upnakc, (2) their involvement in sulfhydryl rcagcnt-mc- 
diatcd glucose transport inhibition using pCMBS, and 
(3) the possible interaction of these residues with trans- 
Amino acid no, Nuclcolidc chanfi Amino acid change 
Cys42l 4TGC3’ 3 S’CGC3 Cys 4 Arg 
cys-429 5TGT3’ -t 51~3’ Cyr 3 Scr 
The mutrgcncsir was confirmed by DNA scqucncc anrlysia with 
upproprintc primers. fhc mutant DNAlr Wcrc subcloncd into the 
oocylc cxprcssion vector pSP64T [IS]. III pcncral. mRNAs wcrc prc- 
purcd from XIJuI-lincarizcd pSF64T according IO the method of Mcl- 
ton cl al. [I61 modillcd by addingO.S/rM ‘mGpppG and 50yM rGTP 
undU.8yCiiml [“S]UTPaB. Quantitrtion ofncwly symhcrizcd mRNA 
was pcrformcd by counting the incorporated [%]UTP. by dctsrmina- 
tion of the OD:, and by cslimfilion of the rcspcclivc mRNAs on a 
dcnaturingaprosc gel using ribosomal283 and IflS rRNA (Phartna- 
cia, Frciburg, Germany) us standards. The iinal conccntalion of 
nclvly synthcsizcd mRNA was adjuatcd to I m~ml. 
cmfe&!lrr &r~; #. #clkr, lnstitut filr Pharmakologic dcr 2.2. Xcnopus 00c_vfes UT expression sybwtt an3 r~utt.tport tttwsutctttm 
Frcicn UnlvcrsitUt Brrlin, Thiclallcc 69-73, D-1000 Berlin 33, Cicr- Collcclion. dcfullicultition und cullurc of A’c’cnopusoecy~cs w rc cun- 
many. duct&l as dcscriixd prcvlously [lo]. Routinely, oosytcs wcrc injcctcd 
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with 50 nl of a ralution contuinin&cuppd mRNA und collcclcd uflcr 
3 days for transport mcururcmcn~r. “C-1nbclcd 3-0methyl-glucose or 
?.dcoxyglucosc uptukc ussnys wcrc conduct&l by maintaining groups 
of up IO 10 oocytcr in motlincd Buabs solution (MBS) nl Q Rnal 
conccmrution of SO BM of the rnpcctivc glusorc malogs. Aftcr the 
indicated lime. the oosytcs wcrc warhcd 3 timer with 3 ml of ice-cold 
MRS solution conluinin& O,I mM phlorclin (l.c. slop solulion) and 
each sinac oocylc was dissolved in 0.5 ml of I+ SRS bcforc quanti- 
tntion of rudiorclivity by a liquid rcintillntion spcctrophotomctcr. 
All subrlraia used wcrc of hiphat Smdc qualily. The mutant ol- 
igonuclco~idcs wcrc purchased from Molbiol UWin, Gcrmunyl, the 
radiol;rbclcd hrxosccu from DuPont (8ud Homburg. Germnny): for 
requcnsiny the Scqucnurc version 2 DNA rqucncina kit WSD. Clcvc- 
lend. USA) was urd. Cytcshalnrin 8. phlorclin and p-chloromsrcuri~ 
bsnzcnc sulfonic acid (pCMB§) arc from Sigma Chcmicatlr (St. Louis. 
USA). Xrrroprrr lurrir frogs wcrc obtained from H. Kllhlcr. Xcnopur 
kborxucht. Hamburg, Cicmrany. Statinisal evaluation HIS made 
using the Student’s / test for puircd v~lucr conducted with SlatVisw 
for the Mncintorh (Abucus Concepts. Inc.), 
3. RESULTS 
Tablc I shows thar mRNAs which hud been in vitro 
transcribed from wild-type Glutl-cDNA or the mutant 
Cys-421- and Cys429-cDNAs were cffisicntly truns- 
latcd to functionally active hctcrologous glucose trans- 
porter proteins in Xmopus oocytcs. No statistically 
significant differences (P>O. 1) of 2.dcoxpo-glucose up- 
take wcrc obscrvcd bctwccn the mutants missing the 
cystcinc residue either at the cxtcrnal loop between 
trnnsmcmbranc segment (TM) 11 and 12 (M429) or at 
the cxofacinl end of the 1 lth TM (M421). and the wild- 
type Glut 1. Thus, neither cystcins residue in position 
421 or 429 appeared to bc csscntial for basal D-gluco?;c 
uptake by the Glut1 glucose rransportcr. 
Fig. I documents that the highly specific thiol-rcagcnt 
pCMBS [17,18]. which very poorly penetrates the 
plasma membrane in intact cells, inhibited glucose up= 
take cxclusivcly by reacting with Cys=429. The 2.dcoxy- 
D-~lusosc uptake was reduced to 28% in Glut I-cxprcss- 
Tublc I 
2-Dcoxy-r~~@xosc uptake of the Cy+421 nad Cyr-429 mutuntr 
29Dcorry-o-gluwrc uptplkc (pmoVoocytcl30 min) 
Exp. 1 
SlIUltt Gllfr I M b2f 
Mcnn 74.3 76.2 
f S,E,M. ::II 6.5 6.5 
Exp. 2 
SlurIll Glur I M 429 
Mann 2,s 14880 125.8 
2 5E.M. 0,3 I I,0 69 
In two independent cxperimcn& Xcnoprrs oocytcr were injcctcd with 
mfcr irimnij or nii%FiA cnticiing ihti CyGtZi g-P^nj and fhcCysGiI 
(C-&) rnulnnts, Three days aficr injsction I.dcoRy-o-[U-“qglucclsc 
(SOyM) uptake WBS pcrfonncd In IO-20 sin& Xe10pu.r oorytcs, !/al- 
ucs rcprcscnt mean I 5.E.M, 
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Fig. 1. ElYcst of pCMBS on 2_dsony+$lucorc uptake. Xcno~us 
oosytcscxprcuing the wild-typ Glu~l. the M42l or the M429 &~coorc 
tranrportcr wcrc cxposcd to the rclativcly imptnncanr rulrhydryl rca- 
gcn~ pCMBS (0.5 mM [ 171) for 30 min at room tcmpsraturc, For each 
group, the pcrccntugr of remaining activity wus calculrrtcd from the 
diffcrcnm of the evcra#cd l~cony-~[U.“C]plucclc(~dM) uptnkc 
of untrr;rtcd and pCMBS+cutcd oocytcr. For the two indcpndcnt 
cxpcrimcntr 8-20 oasyfcs wcrc included in each group. 
ing oocytcs or to 24% in the M421 group (averaged 
value of Exp. 1 and 2). From theses data, Cys-421 is not 
acccssiblc to inhibition by sulfhydyl reagents ar least in 
a conformation of the glucose transporter that favors 
glucose binding from outside rhc plasma membrane (iz. 
influx). As oocytcs from diff’srcnt experiments do not 
necessarily express the same amount of glucose trans- 
porter proteins, for each group a paired somparison 
was conducted between untreated- and pCMBS-treated 
oocytcs, thus setting the non-inhibited 2.dcoxy-o-glu- 
cosc uptake to 100%. 
Obscrvcd in three independent expcrimcnrs, inhibi- 
tion of 3-0-mcthylglucosc transport by the specific 
transport inhibitor CB was always about half as rffcc- 
tivc in M421-expressing Xcrtopus oocytcs when com- 
pared with cells expressing the wild-type or rhc Cys-429 
murant, In Fig. 2 WC compared the remaining transport 
activity at two different conccntrarions of CB. Oocytcs 
from the same frog were used in order to directly com- 
pare the inhibition between the two mutants. 3-O-mcrh- 
ylglucosc transport was inhibited by 62% (Glutl), 76% 
[M429), and 30% (M421) at the lower concentration or 
by 86% (Glutl), 81% (M429), and 57% (M421) at the 
higher concsntration of CB. As shown for both conccn= 
trations, rhc effectiveness of CB-inhibition of glucose 
transport was dependent on the presence of Cys-421 as 
can bc doczxi~cd by ^xiqxxi~g x42! VI. MU’ 
(fQO.01 for 2yM CB; PcO.01 for 20 FM CB) or M42l 
vs. wild-type Glut1 (P=O.Ol for 2 #M CB; EW.01 for 
20 /LM CB). 
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Fig, 2. J-U-Mcthyl&xou tmnsport inhibition by cytochaluin B on 
a=cytcr nprcsring cyrscinc mutants. 3@‘C]Mcthylglucor (9OyM) 
trnnuport array was pcrformcd in Xcnopu oocytca cxprcsinp the 
urild-type Cilul I and rhc Cys42I or Cun429 mutants. Transport wus 
inhibited by CB nt two contcntralionr I2 PM und 20 MM). Values 
prcscnt mean f S.E,M, of 10-20 oocytfri from &ch group. 
4. DISCUSSION 
The importance of the cystcinc residues for the func- 
tion of glucose transporters has been addressed by 
muny authors(rtvicwcd in [§,7,19]), The role ofCys-421 
at the sxofacial end of helix 11 and Cys-429 which is 
located in the cxtraccllular loop between TM I 1 and 12 
has been of primary interest for ligand binding and 
transport inhibition by sulfhydryl reagents. In contrast 
to Cys-207 and Cys-347 thut is conserved in Glutl- 
Glut4, Cys-421 and Cys429 arc cxprcsscd exclusively 
in the Glut1 mnd Glut2 transporters. In accordance with 
their expression in only a limited number of trnnportcr 
isoforms, these cystcins arc not essential for the basal 
glucose transport, 
It has been concluded that among the three cystcins 
of a 19 kBn sarboxy-terminal c eavage fragment Cys- 
429 is the most likely candidate for binding from the 
cxofacial surface of the tranporter [20]. This assump= 
tion, however, has to be confirmed by amino acid 
sequence analysis, As pointed out by others [§,?I addi- 
tional cystcins might bc also cxpoxd during the coniir- 
mational changes of the trans&ortcr. Therefore, it rc- 
maincd to be answered whether under dcfincd condi= 
tions Cys- 421 is also accessible to ligands reacting with 
thiols from outside the sell and/or after covalent binding 
is involved in transport inhibition. PCMBS is known as 
an effective inhibitory reagent which very poorly pcnc- 
trates plasma membranes of intact cells 1171. In a con- 
formation of the transporter ready to bind glucose from 
outside the cell (influx), pCMBS at the used concentrz- 
tion (0.S mM) was without effect on the Cys-429 mu- 
tent, whereas a comparable transport inhibition of both 
Glutl- and M42kexprcssing oocytcs was observed. 
With regard to the altcrneting-conformation mccha- 
nism of transport, further studies will how to bc con- 
ducted to answer the question of whcthcr inhibition 
from outaids the plasma membrane can afTcst the cfllux 
of 8lucosc from the Xcnopw oocytc and vice ~crsa fter 
co-injecting the sulfhydryl rcagcnt into the cells. 
As crystallization of the glucose transporter has still 
failed to succeed. site-directed mutagenesis remains at 
prcscnt the only alternative stratsgy in ardor to study 
structurefunction relationship, It is wdl established 
that CB competitively inhibits glucose transport from 
the cytoplasmic side by binding at or near the inward- 
facing substrate binding site of Glut 1. WC know from 
mutation of all six tryptophans that Trp=388 atthe end 
of helix 10 is involved in the quilibrium binding of CB 
[9]. Substitution of Cys-421 by Arg caused a partial 
protection of the glucose transpart inhibition by this 
specific transport inhibitor. As WC failed to perform CB 
binding in membranes of glucose transportcr-cxprcss- 
ing oocytcs, the putative ffect of this point mutation on 
the Kd for CB remains an open question. However, it 
seems reasonable to assume that Cys-421 exerts a stabi- 
lizing cffcst on the adjacent helix 10 harboring Trp-388. 
Since the replacement of Cys421 cannot completely 
abolish the inhibitory effectiveness of CB, one might 
speculate that either Trp-388 still remains a binding site 
for CB cvcn with lower affinity and/or CB molecules 
that arc bound to othsr domains are additionally in- 
volved. 
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